Leflunomide, Pomalidomide, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma
Status:
Recruiting
Trial end date:
2021-11-01
Target enrollment:
Participant gender:
Summary
This phase II trial studies how well leflunomide, pomalidomide, and dexamethasone work for
the treatment of multiple myeloma that has come back (relapsed) or does not respond to
treatment (refractory). Leflunomide may stop the growth of cancer cells by blocking some of
the enzymes needed for cell growth. Immunotherapy with pomalidomide, may induce changes in
body's immune system and may interfere with the ability of tumor cells to grow and spread.
Chemotherapy drugs, such as dexamethasone, work in different ways to stop the growth of
cancer cells, either by killing the cells, by stopping them from dividing, or by stopping
them from spreading. Giving leflunomide with pomalidomide and dexamethasone may work better
in treating multiple myeloma compared to pomalidomide and dexamethasone alone.